{"protocolSection": {"identificationModule": {"nctId": "NCT00723021", "orgStudyIdInfo": {"id": "B0041002"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "PF-04191834 Single Dose Bronchodilatory Study In Asthma.", "officialTitle": "A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients."}, "statusModule": {"statusVerifiedDate": "2012-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-07-24", "studyFirstSubmitQcDate": "2008-07-24", "studyFirstPostDateStruct": {"date": "2008-07-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-12-27", "resultsFirstSubmitQcDate": "2012-12-27", "resultsFirstPostDateStruct": {"date": "2013-02-01", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2011-03-16", "dispFirstSubmitQcDate": "2011-03-16", "dispFirstPostDateStruct": {"date": "2011-03-28", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-12-27", "lastUpdatePostDateStruct": {"date": "2013-02-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Bronchodilator"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 15, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "PF-04191834 30mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: PF-04191834"]}, {"label": "PF-04191834 100mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: PF-04191834"]}, {"label": "PF-04191834 2000mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: PF-04191834"]}, {"label": "zileuton", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: zileuton"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "PF-04191834", "description": "30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.", "armGroupLabels": ["PF-04191834 30mg"]}, {"type": "DRUG", "name": "PF-04191834", "description": "100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.", "armGroupLabels": ["PF-04191834 100mg"]}, {"type": "DRUG", "name": "PF-04191834", "description": "2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose", "armGroupLabels": ["PF-04191834 2000mg"]}, {"type": "DRUG", "name": "zileuton", "description": "1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.", "armGroupLabels": ["zileuton"]}, {"type": "DRUG", "name": "Placebo", "description": "2 x placebo tablets + placebo oral dispersion, single dose.", "armGroupLabels": ["placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "The FEV1 is the maximal volume of air that can be forcefully exhaled in one second", "timeFrame": "Baseline, 12 hours (hrs) post-dose"}, {"measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "The FEV1 is the maximal volume of air that can be forcefully exhaled in one second", "timeFrame": "Baseline, 24 hours (hrs) post-dose"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible", "timeFrame": "Baseline, 12 hours (hrs) post-dose"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible", "timeFrame": "Baseline,24 hours (hrs) post-dose"}, {"measure": "Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)", "description": "The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity", "timeFrame": "Baseline, 12 hours (hrs) post-dose"}, {"measure": "Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)", "description": "The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity", "timeFrame": "Baseline, 24 hours (hrs) post-dose"}], "otherOutcomes": [{"measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period."}, {"measure": "Maximum Observed Plasma Concentration (Cmax)", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period."}, {"measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period."}, {"measure": "Plasma Decay Half-Life (t1/2)", "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period."}, {"measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", "timeFrame": "14 and 24 hours following dosing in each period."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Persistent mild/moderate asthma for at least 6 months.\n* Reduced lung function\n* Reversible airway obstruction\n\nExclusion Criteria:\n\n* Pregnant/nursing females.\n* Liver function tests greater than upper limit of normal (ULN)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pfizer Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21225", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Pfizer Investigational Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Pfizer Investigational Site", "city": "Kalamazoo", "state": "Michigan", "zip": "49007", "country": "United States", "geoPoint": {"lat": 42.29171, "lon": -85.58723}}, {"facility": "Pfizer Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0041002&StudyName=PF-04191834%20Single%20Dose%20Bronchodilatory%20Study%20In%20Asthma."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Treatment Sequence 1", "description": "Placebo/Zileuton CR 1200 mg/PF-04191834 30 mg/PF-04191834 2000 mg/PF-04191834 100 mg"}, {"id": "FG001", "title": "Treatment Sequence 2", "description": "PF-04191834 100 mg/PF-04191834 30 mg/PF-04191834 2000 mg/Placebo/Zileuton CR 1200 mg"}, {"id": "FG002", "title": "Treatment Sequence 3", "description": "PF-04191834 2000 mg/PF-04191834 100 mg/Zileuton CR 1200 mg/PF-04191834 30 mg/Placebo"}, {"id": "FG003", "title": "Treatment Sequence 4", "description": "PF-04191834 30 mg/Placebo/PF-04191834 100 mg/Zileuton CR 1200 mg/PF-04191834 2000 mg"}, {"id": "FG004", "title": "Treatment Sequence 5", "description": "Zileuton CR 1200 mg/PF-04191834 2000 mg/Placebo/PF-04191834 100 mg/PF-04191834 30 mg"}], "periods": [{"title": "Intervention Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Intervention Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Intervention Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Intervention Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}]}, {"title": "Intervention Period 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "Participants receiving any of the 5 treatments (PF-04191834 30 mg, PF-04191834 100 mg, PF-04191834 2000 mg, Zileuton CR 1200 mg and Placebo) in a randomized fashion first"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.5", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "The FEV1 is the maximal volume of air that can be forcefully exhaled in one second", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline, 12 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.624", "spread": "0.3939"}, {"groupId": "OG001", "value": "2.626", "spread": "0.3860"}, {"groupId": "OG002", "value": "2.585", "spread": "0.5200"}, {"groupId": "OG003", "value": "2.579", "spread": "0.4131"}, {"groupId": "OG004", "value": "2.609", "spread": "0.4502"}]}]}, {"title": "Change at 12 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.064", "spread": "0.3098"}, {"groupId": "OG001", "value": "0.164", "spread": "0.1859"}, {"groupId": "OG002", "value": "0.152", "spread": "0.2072"}, {"groupId": "OG003", "value": "0.265", "spread": "0.3047"}, {"groupId": "OG004", "value": "0.131", "spread": "0.1566"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", "description": "The FEV1 is the maximal volume of air that can be forcefully exhaled in one second", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline, 24 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.624", "spread": "0.3939"}, {"groupId": "OG001", "value": "2.626", "spread": "0.3860"}, {"groupId": "OG002", "value": "2.585", "spread": "0.5200"}, {"groupId": "OG003", "value": "2.579", "spread": "0.4131"}, {"groupId": "OG004", "value": "2.609", "spread": "0.4502"}]}]}, {"title": "Change at 24 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.122", "spread": "0.2553"}, {"groupId": "OG001", "value": "0.014", "spread": "0.2318"}, {"groupId": "OG002", "value": "0.103", "spread": "0.2616"}, {"groupId": "OG003", "value": "0.162", "spread": "0.1559"}, {"groupId": "OG004", "value": "0.151", "spread": "0.1338"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline, 12 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each subject received 2 x placebo tablets ( for zileuton 600 mg tablets) + placebo oral dispersion (for PF-04191834), single dose"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Each subject received PF-04191834 30 mg, single dose, oral dispersion + 2 x placebo tablets"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Each subject received PF-04191834 100 mg, single dose, oral disersion + 2 x placebo tablets, single dose"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Each subject received zileuton CR 1200 mg, 2x600 mg tablets, single dose + placebo oral dispersion, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.852", "spread": "0.8865"}, {"groupId": "OG001", "value": "3.891", "spread": "0.8625"}, {"groupId": "OG002", "value": "3.720", "spread": "0.8930"}, {"groupId": "OG003", "value": "3.792", "spread": "0.9100"}, {"groupId": "OG004", "value": "3.821", "spread": "0.9914"}]}]}, {"title": "Change at 12 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.025", "spread": "0.3306"}, {"groupId": "OG001", "value": "0.284", "spread": "0.4150"}, {"groupId": "OG002", "value": "0.210", "spread": "0.4792"}, {"groupId": "OG003", "value": "0.266", "spread": "0.3184"}, {"groupId": "OG004", "value": "0.140", "spread": "0.2750"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC)", "description": "The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline,24 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.852", "spread": "0.8865"}, {"groupId": "OG001", "value": "3.891", "spread": "0.8625"}, {"groupId": "OG002", "value": "3.720", "spread": "0.8930"}, {"groupId": "OG003", "value": "3.792", "spread": "0.9100"}, {"groupId": "OG004", "value": "3.821", "spread": "0.9914"}]}]}, {"title": "Change at 24 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.162", "spread": "0.2322"}, {"groupId": "OG001", "value": "0.051", "spread": "0.2839"}, {"groupId": "OG002", "value": "0.229", "spread": "0.3657"}, {"groupId": "OG003", "value": "0.171", "spread": "0.2070"}, {"groupId": "OG004", "value": "0.219", "spread": "0.2977"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)", "description": "The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/Sec", "timeFrame": "Baseline, 12 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Each subject received 2 x placebo tablets ( for zileuton 600 mg tablets) + placebo oral dispersion (for PF-04191834), single dose"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Each subject received PF-04191834 30 mg, single dose, oral dispersion + 2 x placebo tablets"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Each subject received PF-04191834 100 mg, single dose, oral disersion + 2 x placebo tablets, single dose"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Each subject received zileuton CR 1200 mg, 2x600 mg tablets, single dose + placebo oral dispersion, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.951", "spread": "0.4550"}, {"groupId": "OG001", "value": "1.901", "spread": "0.4228"}, {"groupId": "OG002", "value": "1.807", "spread": "0.4452"}, {"groupId": "OG003", "value": "1.915", "spread": "0.4488"}, {"groupId": "OG004", "value": "1.959", "spread": "0.4378"}]}]}, {"title": "Change at 12 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.091", "spread": "0.3556"}, {"groupId": "OG001", "value": "0.340", "spread": "0.4238"}, {"groupId": "OG002", "value": "0.269", "spread": "0.3033"}, {"groupId": "OG003", "value": "0.297", "spread": "0.3871"}, {"groupId": "OG004", "value": "0.187", "spread": "0.3757"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Flow Between 25 and 75% of Vital Capacity (FEF25-75)", "description": "The FEF25-75 is the forced expiratory flow between 25 and 75% of vital capacity", "populationDescription": "All enrolled participants treated who had at least 1 concentration in at least 1 treatment period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline, 24 hours (hrs) post-dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received a single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period"}, {"id": "OG001", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG002", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}, {"id": "OG004", "title": "Zileuton CR 1200 mg", "description": "Paticipants received a single oral dose of zileuton CR 1200 mg (2 x 600 mg tablets) in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "15"}, {"groupId": "OG003", "value": "15"}, {"groupId": "OG004", "value": "15"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.951", "spread": "0.4550"}, {"groupId": "OG001", "value": "1.901", "spread": "0.4228"}, {"groupId": "OG002", "value": "1.807", "spread": "0.4452"}, {"groupId": "OG003", "value": "1.915", "spread": "0.4488"}, {"groupId": "OG004", "value": "1.959", "spread": "0.4378"}]}]}, {"title": "Change at 24 Hours Postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.146", "spread": "0.3049"}, {"groupId": "OG001", "value": "0.038", "spread": "0.1952"}, {"groupId": "OG002", "value": "0.196", "spread": "0.2169"}, {"groupId": "OG003", "value": "0.151", "spread": "0.2030"}, {"groupId": "OG004", "value": "0.208", "spread": "0.3483"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", "populationDescription": "All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.", "groups": [{"id": "OG000", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG001", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG002", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1979", "spread": "482"}, {"groupId": "OG001", "value": "5547", "spread": "1388"}, {"groupId": "OG002", "value": "29990", "spread": "8812"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Maximum Observed Plasma Concentration (Cmax)", "populationDescription": "All enrolled subjects treated who have at least one of the PK parameters of interest in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.", "groups": [{"id": "OG000", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG001", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG002", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "154", "spread": "29"}, {"groupId": "OG001", "value": "426", "spread": "118"}, {"groupId": "OG002", "value": "2146", "spread": "410"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hrs", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.", "groups": [{"id": "OG000", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG001", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG002", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6", "lowerLimit": "5", "upperLimit": "14"}, {"groupId": "OG001", "value": "6", "lowerLimit": "4", "upperLimit": "14"}, {"groupId": "OG002", "value": "10", "lowerLimit": "4", "upperLimit": "14"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Plasma Decay Half-Life (t1/2)", "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", "populationDescription": "Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be \\>10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.", "reportingStatus": "POSTED", "timeFrame": "Pre-dose, 2, 4, 5, 6, 10, 14 and 24 hours following dosing in each period.", "groups": [{"id": "OG000", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG001", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG002", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", "populationDescription": "Since the PK sample collection only occurred until 24 hours and the approximate t1/2 at all doses appeared to be \\>10 hours, t1/2 and area under the plasma concentration versus time curve until infinity (AUCinf) are not reported at any dose level.", "reportingStatus": "POSTED", "timeFrame": "14 and 24 hours following dosing in each period.", "groups": [{"id": "OG000", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period"}, {"id": "OG001", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period"}, {"id": "OG002", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received single oral dose of placebo for zileuton CR tablets or placebo for PF-04191834 oral aqueous dispersion in any treatment period", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 9, "otherNumAtRisk": 15}, {"id": "EG001", "title": "PF-04191834 30 mg", "description": "Participants received a single oral dose of PF-04191834 30 mg in any treatment period", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 4, "otherNumAtRisk": 14}, {"id": "EG002", "title": "PF-04191834 100 mg", "description": "Participants received a single oral dose of PF-04191834 100 mg single dose in any treatment period", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 10, "otherNumAtRisk": 15}, {"id": "EG003", "title": "PF-04191834 2000 mg", "description": "Participants received a single oral dose of PF-04191834 2000 mg in any treatment period", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 4, "otherNumAtRisk": 15}, {"id": "EG004", "title": "Zileuton CR 1200 mg", "description": "Paticipants received single oral dose of zileuton CR1200 mg (2 x 600 mg tablets) in any treatment period", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 12, "otherNumAtRisk": 15}], "otherEvents": [{"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Viral upper respiratory tract", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Electrocardiogram abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 15}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 15}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v12.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 14}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000063449", "term": "Zileuton"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000016859", "term": "Lipoxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M245553", "name": "Zileuton", "asFound": "Nepafenac", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}